Physician profile
Mark Pankonin
NPI 1356509947
$1,272.74
in general payments reported to CMS, 2019-2025
14 companies · $42.69 in 2025
The $42.69 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $130 · 2021: $421 · 2022: $235 · 2023: $89.84 · 2024: $41.36 · 2025: $42.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $173.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.55 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Celgene Corporation | $103.95 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.91 | 2019-2021 | |
| Janssen Biotech, INC. | $84.61 | 2021-2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $45.90 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $42.69 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $32.65 | 2020-2021 | |
| Pfizer INC. | $30.13 | 2019-2022 | |
| Ucb, INC. | $29.74 | 2019-2020 | |
| Gilead Sciences, INC. | $23.58 | 2022 | |
| Qol Medical, LLC | $19.47 | 2021 | |
| Boston Scientific Corporation | $18.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pankonin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.